nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-244-12-68-76nogr-3281Research ArticleОБЗОРREVIEWВоспалительные заболевания кишечника у беременных: проблемы и решенияInfl ammatory bowel disease during pregnancy: problems and conclusionshttps://orcid.org/0000-0002-5056-4504КозловаИ. В.KozlovaI. V.kozlova@inbox.ruhttps://orcid.org/0000-0002-3264-6637КарповМ. Е.KarpovM. E.noemail@neicon.ruhttps://orcid.org/0000-0002-4654-9344ПахомоваА. Л.PakhomovaA. L.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава РоссииРоссияSaratov State Medical University named after V.I. Razumovsky (Razumovsky University)Russian Federation2025260220260126876Copyright © Козлова И.В., Карпов М.Е., Пахомова А.Л., 20262026Козлова И.В., Карпов М.Е., Пахомова А.Л.Kozlova I.V., Karpov M.E., Pakhomova A.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3281

В обзорной статье представлен анализ подходов к ведению беременных с воспалительными заболеваниями кишечника на примере клинического случая пациентки с язвенным колитом. Проанализированы аспекты прегравидарной подготовки, особенности течения беременности и послеродового периода, уделено внимание особенностям диагностики и лечения беременных с язвенным колитом и болезнью Крона. Обзор основан на результатах опубликованных отечественных и международных методических и клинических рекомендаций, популяционных и наблюдательных исследований и может стать подспорьем в работе со сложным контингентом пациенток.

The review article presents an analysis of approaches to the management of pregnant women with inflammatory bowel diseases using the example of a clinical case of a patient with ulcerative colitis. The analysis focuses on various aspects of pre-pregnancy preparation, the progression of pregnancy, and the postpartum period. Additionally, it highlights the distinctive characteristics of diagnosing and treating pregnant women with ulcerative colitis and Crohn’s disease. The review is based on the results of published domestic and international methodological and clinical recommendations, population-based and observational studies and can be helpful in working with a complex contingent of patients.

воспалительные заболевания кишечникабеременностьязвенный колитболезнь Кронадиагностикалечениеinflammatory bowel diseasepregnancyulcerative colitisCrohn’s diseasediagnosticstreatmentReferencesDignass A., Eliakim R., Magro F. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J. Crohns Colitis. 2012; 6(10):965-990. doi: 10.1016/j.crohns.2012.09.003.Dignass A., Eliakim R., Magro F. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J. Crohns Colitis. 2012; 6(10):965-990. doi: 10.1016/j.crohns.2012.09.003.Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140:1785-1794. doi: 10.1053/j.gastro.2011.01.055.Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140:1785-1794. doi: 10.1053/j.gastro.2011.01.055.Molodecky N., Soon I., Rabi D. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology. 2012; 142(1):46-54. doi: 10.1053/j.gastro.2011.10.001.Molodecky N., Soon I., Rabi D. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology. 2012; 142(1):46-54. doi: 10.1053/j.gastro.2011.10.001.Qiu Y., Wen Ren W., Liu Y. et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. E Clinical Medicine, 2020; 27:100544. doi: 10.1016/j.eclinm.2020.100544.Qiu Y., Wen Ren W., Liu Y. et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. E Clinical Medicine, 2020; 27:100544. doi: 10.1016/j.eclinm.2020.100544.Belousova E.A., Abdulganieva D.I., Alexeeva O.P. et al. Social and demographic characteristics, Features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. Almanac of Clinical Medicine. 2018; 46(5): 445-463. (In Russ.) doi: 10.18786/2072-0505-2018-46-5-445-463.@@ Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018; 46(5):445-463. doi: 10.18786/2072-0505-2018-46-5-445-463.Belousova E.A., Abdulganieva D.I., Alexeeva O.P. et al. Social and demographic characteristics, Features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. Almanac of Clinical Medicine. 2018; 46(5): 445-463. (In Russ.) doi: 10.18786/2072-0505-2018-46-5-445-463.@@ Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018; 46(5):445-463. doi: 10.18786/2072-0505-2018-46-5-445-463.Burisch J., Pedersen N., Čuković-Čavka S. et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut. 2014; 63(4):588-597. doi: 10.1136/gutjnl-2013-304636.Burisch J., Pedersen N., Čuković-Čavka S. et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut. 2014; 63(4):588-597. doi: 10.1136/gutjnl-2013-304636.Hudson M., Flett G., Sinclair T.S. et al. Fertility and pregnancy in inflammatory bowel disease.Int. J. Gynaecol. Obstet. 1997. 58(2): 229-237. doi: 10.1186/ar1957.Hudson M., Flett G., Sinclair T.S. et al. Fertility and pregnancy in inflammatory bowel disease.Int. J. Gynaecol. Obstet. 1997. 58(2): 229-237. doi: 10.1186/ar1957.Ostensen M., Khamashta M., Lockshin M. et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 2006; 8(3): 209. doi: 10.1186/ar1957.Ostensen M., Khamashta M., Lockshin M. et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 2006; 8(3): 209. doi: 10.1186/ar1957.Nielsen O.H., Andreasson B., Bondesen S. et al. Pregnancy in ulcerative colitis. Scand. J Gastroenterol. 1983; 18(6): 735-742. doi: 10.3109/00365528309182088.Nielsen O.H., Andreasson B., Bondesen S. et al. Pregnancy in ulcerative colitis. Scand. J Gastroenterol. 1983; 18(6): 735-742. doi: 10.3109/00365528309182088.Şenateş E., Zolak Y., Erdem E.D. et al. Serum anti-Mullerian hormone levels are lower in reproductive-age women with Crohn’s disease compared to healthy control women. Journal of Crohn’s & Colitis, 2013; (7): 29-34. doi: 10.1016/j.crohns.2012.03.003.Şenateş E., Zolak Y., Erdem E.D. et al. Serum anti-Mullerian hormone levels are lower in reproductive-age women with Crohn’s disease compared to healthy control women. Journal of Crohn’s & Colitis, 2013; (7): 29-34. doi: 10.1016/j.crohns.2012.03.003.Roseira J., Magro F., Fernandes S. et al. Sexual quality of life in inflammatory bowel disease: a multicenter, national-level study. Inflamm. Bowel Dis. 2020; 26: 746-755. doi: 10.1093/ibd/izz185.Roseira J., Magro F., Fernandes S. et al. Sexual quality of life in inflammatory bowel disease: a multicenter, national-level study. Inflamm. Bowel Dis. 2020; 26: 746-755. doi: 10.1093/ibd/izz185.Ban L., Tata L.J., Humes D.J. et al. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol. Ther. 2015; (42): 855-866. doi: 10.1111/apt.13354.Ban L., Tata L.J., Humes D.J. et al. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol. Ther. 2015; (42): 855-866. doi: 10.1111/apt.13354.Torres J., Chaparro M., Julsgaard et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. Journal of Crohn’s and Colitis. 2023; 17(1): 1-27. doi: 10.1093/ecco-jcc/jjac115.Torres J., Chaparro M., Julsgaard et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. Journal of Crohn’s and Colitis. 2023; 17(1): 1-27. doi: 10.1093/ecco-jcc/jjac115.Ghosh S., Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations [EFCCA] patient survey. J. Crohns Colitis. 2007; 1:10-20. doi: 10.1016/j.crohns.2007.06.005.Ghosh S., Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations [EFCCA] patient survey. J. Crohns Colitis. 2007; 1:10-20. doi: 10.1016/j.crohns.2007.06.005.Zapata L. B., Paulen M.E., Cansino C. et al. Contraceptive use among women with inflammatory bowel disease: a systematic review. Contraception. 2010; 82: 72-85. doi: 10.1016/j.contraception.2010.02.012.Zapata L. B., Paulen M.E., Cansino C. et al. Contraceptive use among women with inflammatory bowel disease: a systematic review. Contraception. 2010; 82: 72-85. doi: 10.1016/j.contraception.2010.02.012.Ananthakrishnan A. N., Zadvornova Y., Naik A.S. et al. Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. Journal of digestive diseases. 2012; 13: 472-477. doi: 10.1111/j.1751-2980.2012.00618.x.Ananthakrishnan A. N., Zadvornova Y., Naik A.S. et al. Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. Journal of digestive diseases. 2012; 13: 472-477. doi: 10.1111/j.1751-2980.2012.00618.x.Sunanda V. Kane, MD, MSPH. The Safety of Treating IBD During Pregnancy. Digestive Disease Week (DDW). 2014.Sunanda V. Kane, MD, MSPH. The Safety of Treating IBD During Pregnancy. Digestive Disease Week (DDW). 2014.Caprilli R., Gassull M.A., Escher J.C. et al. European Crohn’s and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006; 55(1): 36-58. doi: 10.1136/gut.2005.081950c.Caprilli R., Gassull M.A., Escher J.C. et al. European Crohn’s and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006; 55(1): 36-58. doi: 10.1136/gut.2005.081950c.Norgard B., Puho E., Pedersen L. et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. American Journal of Gastroenterology. 2003; 98: 2006-2010. doi: 10.1111/j.1572-0241.2003.07578.x.Norgard B., Puho E., Pedersen L. et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. American Journal of Gastroenterology. 2003; 98: 2006-2010. doi: 10.1111/j.1572-0241.2003.07578.x.Riis L., Vind I., Politi P. et al. On behalf of the European Collaborative study group on inflammatory bowel disease (EC-IBD). Does pregnancy change the disease course? A Study in a European Cohort of Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology. 2006; 101: 1539-1545. doi: 10.1111/j.1572-0241.2006.00602.x.Riis L., Vind I., Politi P. et al. On behalf of the European Collaborative study group on inflammatory bowel disease (EC-IBD). Does pregnancy change the disease course? A Study in a European Cohort of Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology. 2006; 101: 1539-1545. doi: 10.1111/j.1572-0241.2006.00602.x.Uspenskaya Yu.B. Inflammatory bowel diseases and pregnancy: scientific and practical monograph. Moscow: Prima Print Publishing. 2015, pp.40. (In Russ.) Available at: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdf@@ Успенская Ю.Б. Воспалительные заболевания кишечника и беременность: научно-практическая монография. Москва: Издательство «Прима Принт». 2015; 40. URL: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdfUspenskaya Yu.B. Inflammatory bowel diseases and pregnancy: scientific and practical monograph. Moscow: Prima Print Publishing. 2015, pp.40. (In Russ.) Available at: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdf@@ Успенская Ю.Б. Воспалительные заболевания кишечника и беременность: научно-практическая монография. Москва: Издательство «Прима Принт». 2015; 40. URL: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdfQuan W.L., Chia C.K., Yim H.B. Safety of endoscopical procedures during pregnancy. Singapore Medical Journal. 2006; 47: 525-528. doi: 10.7759/cureus.6301.Quan W.L., Chia C.K., Yim H.B. Safety of endoscopical procedures during pregnancy. Singapore Medical Journal. 2006; 47: 525-528. doi: 10.7759/cureus.6301.Mahadevan U. et al. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients with Inflammatory Bowel Disease. Gastroenterology. 2017; 152: 451-462. doi: 10.1053/j.gastro.2016.10.013.Mahadevan U. et al. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients with Inflammatory Bowel Disease. Gastroenterology. 2017; 152: 451-462. doi: 10.1053/j.gastro.2016.10.013.Park-Wyllie L., Mazzotta P., Pastuszak A. et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62: 385-392. doi: 10.1002/1096-9926(200012)62:6<385:: AID-TERA5>3.0.CO;2-Z.Park-Wyllie L., Mazzotta P., Pastuszak A. et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62: 385-392. doi: 10.1002/1096-9926(200012)62:6<385:: AID-TERA5>3.0.CO;2-Z.Hviid A., Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011; 183: 796-804. doi: 10.1503/cmaj.101063.Hviid A., Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011; 183: 796-804. doi: 10.1503/cmaj.101063.Moscow City Health Department. Guidelines “Inflammatory Bowel Diseases and Pregnancy”. State Budgetary Healthcare Institution of the City of Moscow “A.S. Loginov Moscow Clinical Scientific and Practical Center of the Moscow City Health Department”. 2024; (In Russ.) Available at: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdf@@ Департамент здравоохранения города Москвы. Методические рекомендации «Воспалительные заболевания кишечника и беременность». Государственное бюджетное учреждение здравоохранения города Москвы «Московский клинический научно-практический центр имени А.С. Логинова Департамента здравоохранения города Москвы». 2024. URL: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdfMoscow City Health Department. Guidelines “Inflammatory Bowel Diseases and Pregnancy”. State Budgetary Healthcare Institution of the City of Moscow “A.S. Loginov Moscow Clinical Scientific and Practical Center of the Moscow City Health Department”. 2024; (In Russ.) Available at: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdf@@ Департамент здравоохранения города Москвы. Методические рекомендации «Воспалительные заболевания кишечника и беременность». Государственное бюджетное учреждение здравоохранения города Москвы «Московский клинический научно-практический центр имени А.С. Логинова Департамента здравоохранения города Москвы». 2024. URL: https://niioz.ru/upload/iblock/753/753f368f41a5512fd2b3a1bd4ff33c21.pdfHutson J. R., Matlow J.N., Moretti M.E., Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J. Obstet. Gynaecology. 2013; 33(1): 1-8. doi: 10.3109/01443615.2012.716106.Hutson J. R., Matlow J.N., Moretti M.E., Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J. Obstet. Gynaecology. 2013; 33(1): 1-8. doi: 10.3109/01443615.2012.716106.Flanagan E. et al. aternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary Pharmacology & Therapeutics. 2021; 53(7): 810-820. doi: 10.1111/apt.16294.Flanagan E. et al. aternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary Pharmacology & Therapeutics. 2021; 53(7): 810-820. doi: 10.1111/apt.16294.Branche J., Cortot A., Bourreille A. et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflammatory bowel disease. 2009; 15(7): 1044. doi: 10.1002/ibd.20858.Branche J., Cortot A., Bourreille A. et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflammatory bowel disease. 2009; 15(7): 1044. doi: 10.1002/ibd.20858.Bar Oz, B., Hackman R., Einarson T., Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001; 71(8): 1051-1055. doi: 10.1097/00007890-200104270-00006.Bar Oz, B., Hackman R., Einarson T., Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001; 71(8): 1051-1055. doi: 10.1097/00007890-200104270-00006.Baumgart D.C., Sturm A., Wiedenmann B., Dignass A.U. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut. 2005; 54:1822-1823. doi: 10.1136/gut.2005.078972.Baumgart D.C., Sturm A., Wiedenmann B., Dignass A.U. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut. 2005; 54:1822-1823. doi: 10.1136/gut.2005.078972.Ministry of Health of the Russian Federation. Clinical guidelines “Ulcerative colitis”.Russian Gastroenterological Association. Age group: adults. 2024; (In Russ.) Available: https://diseases.medelement.com/disease/язвенный-колит-кп-рф-2024/18016.@@ Министерство здравоохранения Российской Федерации. Клинические рекомендации «Язвенный колит». Российская гастроэнтерологическая ассоциация. Возрастная группа: взрослые. 2024. URL доступа: https://diseases.medelement.com/disease/язвенный-колит-кп-рф-2024/18016.Ministry of Health of the Russian Federation. Clinical guidelines “Ulcerative colitis”.Russian Gastroenterological Association. Age group: adults. 2024; (In Russ.) Available: https://diseases.medelement.com/disease/язвенный-колит-кп-рф-2024/18016.@@ Министерство здравоохранения Российской Федерации. Клинические рекомендации «Язвенный колит». Российская гастроэнтерологическая ассоциация. Возрастная группа: взрослые. 2024. URL доступа: https://diseases.medelement.com/disease/язвенный-колит-кп-рф-2024/18016.Mariette X., Förger F., Vasiliauskas E. et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 2006; 4: 1255-1258. doi: 10.1016/j.cgh.2006.07.018.Mariette X., Förger F., Vasiliauskas E. et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 2006; 4: 1255-1258. doi: 10.1016/j.cgh.2006.07.018.Mahadevan U., Wolf D.C., Dubinsky M. et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013; 11: 286-292. doi: 10.1016/j.cgh.2012.11.011.Mahadevan U., Wolf D.C., Dubinsky M. et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013; 11: 286-292. doi: 10.1016/j.cgh.2012.11.011.Zelinkova Z., van der Ent C., Bruin K.F. et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin. Gastroenterol. Hepatol. 2013; 11:318-321. doi: 10.1016/j.cgh.2012.10.024.Zelinkova Z., van der Ent C., Bruin K.F. et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin. Gastroenterol. Hepatol. 2013; 11:318-321. doi: 10.1016/j.cgh.2012.10.024.Schnitzler F., Fidder H., Ferrante M. et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm. Bowel Dis. 2011; 17: 1846-1854. doi: 10.1002/ibd.21583.Schnitzler F., Fidder H., Ferrante M. et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm. Bowel Dis. 2011; 17: 1846-1854. doi: 10.1002/ibd.21583.Mahadevan U., Martin C.F., Sandler R.S. et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012; 142: 149 doi: 10.1016/S0016-5085(12)60561-7.Mahadevan U., Martin C.F., Sandler R.S. et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012; 142: 149 doi: 10.1016/S0016-5085(12)60561-7.Abraham B. et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann. Rheum. Dis. 2017; 10: 1-6. doi: 10.1136/annrheumdis-2017-212196.Abraham B. et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann. Rheum. Dis. 2017; 10: 1-6. doi: 10.1136/annrheumdis-2017-212196.Mahadevan U., Vermeire S., Lasch K. et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Alimentary Pharmocology and Therapeutics. 2017; 45(7): 941-950. doi: 10.1111/apt.13960.Mahadevan U., Vermeire S., Lasch K. et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Alimentary Pharmocology and Therapeutics. 2017; 45(7): 941-950. doi: 10.1111/apt.13960.Moens A. et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Alimentary Pharmocology and Therapeutics. 2020; 51: 129-138. doi: 10.1111/apt.15539.Moens A. et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Alimentary Pharmocology and Therapeutics. 2020; 51: 129-138. doi: 10.1111/apt.15539.Gaidos J.K.J., Kane S.V. Managing IBD Therapies in Pregnancy. Curr. Treat. Options Gastroenterol. 2017; 15(1): 71-83. doi: 10.1007/s11938-017-0123-5.Gaidos J.K.J., Kane S.V. Managing IBD Therapies in Pregnancy. Curr. Treat. Options Gastroenterol. 2017; 15(1): 71-83. doi: 10.1007/s11938-017-0123-5.Yefet E., Schwartz N., Chazan B. et al. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. British Journal of Gastroenterology. 2018; 125: 1069-1076. doi: 10.1111/1471-0528.15119.Yefet E., Schwartz N., Chazan B. et al. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. British Journal of Gastroenterology. 2018; 125: 1069-1076. doi: 10.1111/1471-0528.15119.Prakash P., Dua A., Blumenfeld Y. et al. Longitudinal Trends in Pregnancy Outcomes Among Women With Inflammatory Bowel Disease in the Era of Biologics: A 20-Year Nationwide Analysis. Inflamm. Bowel Dis. 2023. doi: 10.1093/ibd/izad250.Prakash P., Dua A., Blumenfeld Y. et al. Longitudinal Trends in Pregnancy Outcomes Among Women With Inflammatory Bowel Disease in the Era of Biologics: A 20-Year Nationwide Analysis. Inflamm. Bowel Dis. 2023. doi: 10.1093/ibd/izad250.Rolnik D.L., Wright D., Poon L.C. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine. 2017; 377(7): 613-622. doi: 10.1056/NEJMoa1704559.Rolnik D.L., Wright D., Poon L.C. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine. 2017; 377(7): 613-622. doi: 10.1056/NEJMoa1704559.Czeizel A.E., Rockenbauer M. A population-based case-control teratologic study of oral metronidazole treatment during pregnancy. Br.J. Obstet. Gynaecol. 1998; 105(3): 322-327. doi: 10.1111/j.1471-0528.1998.tb10094.x.Czeizel A.E., Rockenbauer M. A population-based case-control teratologic study of oral metronidazole treatment during pregnancy. Br.J. Obstet. Gynaecol. 1998; 105(3): 322-327. doi: 10.1111/j.1471-0528.1998.tb10094.x.Koss C.A., Baras D.C., Lane S.D. et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob. Agents Chemother. 2012; 56(9): 4800-4805. doi: 10.1128/AAC.06477-11.Koss C.A., Baras D.C., Lane S.D. et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob. Agents Chemother. 2012; 56(9): 4800-4805. doi: 10.1128/AAC.06477-11.van der Woude C.J., Ardizzone S., Bengtson M.B. et al. The Second European Evidenced Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis. 2015; 1-18. doi: 10.1093/ecco-jcc/jju006.van der Woude C.J., Ardizzone S., Bengtson M.B. et al. The Second European Evidenced Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis. 2015; 1-18. doi: 10.1093/ecco-jcc/jju006.Rajaratnam S.G., Eglinton T.W., Hider P. et al. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review.Int. J. Colorectal Dis. 2011; 26: 1365-1374. doi: 10.1007/s00384-011-1274-9.Rajaratnam S.G., Eglinton T.W., Hider P. et al. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review.Int. J. Colorectal Dis. 2011; 26: 1365-1374. doi: 10.1007/s00384-011-1274-9.Johnson P., Richard C., Ravid A. et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon. Rectum. 2004; 47: 1119-1126. doi: 10.1007/s10350-004-0570-7.Johnson P., Richard C., Ravid A. et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon. Rectum. 2004; 47: 1119-1126. doi: 10.1007/s10350-004-0570-7.Pachler F.R., Bisgaard T., Mark-Christensen A. et al. Impact on fertility after failure of restorative proctocolectomy in men and women with ulcerative colitis: a 17-year cohort study. Dis. Colon. Rectum. 2020; 63: 816-822. doi: 10.1097/DCR.0000000000001640.Pachler F.R., Bisgaard T., Mark-Christensen A. et al. Impact on fertility after failure of restorative proctocolectomy in men and women with ulcerative colitis: a 17-year cohort study. Dis. Colon. Rectum. 2020; 63: 816-822. doi: 10.1097/DCR.0000000000001640.Order of the Ministry of Health and Social Development of Russia of 03.12.2007 No. 736; (In Russ.) Available at: “On approval of the list of medical indications for artificial abortion”. https://normativ.kontur.ru/document?moduleId=1&documentId=193660.@@ Приказ Минздравсоцразвития России от 03.12.2007 г. № 736 «Об утверждении перечня медицинских показаний для искусственного прерывания беременности». URL доступа: https://normativ.kontur.ru/document?moduleId=1&documentId=193660Order of the Ministry of Health and Social Development of Russia of 03.12.2007 No. 736; (In Russ.) Available at: “On approval of the list of medical indications for artificial abortion”. https://normativ.kontur.ru/document?moduleId=1&documentId=193660.@@ Приказ Минздравсоцразвития России от 03.12.2007 г. № 736 «Об утверждении перечня медицинских показаний для искусственного прерывания беременности». URL доступа: https://normativ.kontur.ru/document?moduleId=1&documentId=193660Lepistc A., Sarna S., Tiitinen A. et al. Female fertility and childbirth after ileal pouch-anal anastomosis for ulcerative colitis. Britain Journal of Surgery. 2007; 94:478-482. doi: 10.1002/bjs.5509.Lepistc A., Sarna S., Tiitinen A. et al. Female fertility and childbirth after ileal pouch-anal anastomosis for ulcerative colitis. Britain Journal of Surgery. 2007; 94:478-482. doi: 10.1002/bjs.5509.Mahadevan U. et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019; 156:508-1524. doi: 10.1053/j.gastro.2018.12.022.Mahadevan U. et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019; 156:508-1524. doi: 10.1053/j.gastro.2018.12.022.Manosa M., Navarro-Llavat M. et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scandinavian Journal of Gastroenterology. 2013; 48:427-432. doi: 10.3109/00365521.2013.772229.Manosa M., Navarro-Llavat M. et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scandinavian Journal of Gastroenterology. 2013; 48:427-432. doi: 10.3109/00365521.2013.772229.Orholm M., Munkholm P., Langholz E. et al. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991; 324:84-88. doi: 10.1056/NEJM199101103240203.Orholm M., Munkholm P., Langholz E. et al. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991; 324:84-88. doi: 10.1056/NEJM199101103240203.Joossens M., Van Steen K., Branche J. et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn’s disease. Inflamm Bowel Dis. 2010;16:58-67. doi: 10.1002/ibd.20985.Joossens M., Van Steen K., Branche J. et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn’s disease. Inflamm Bowel Dis. 2010;16:58-67. doi: 10.1002/ibd.20985.

The authors declare that there are no conflicts of interest present.